Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Fineline Cube Feb 6, 2026
Company Deals

Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics

Fineline Cube Feb 6, 2026
Company Deals Digital

XtalPi Partners with Visen Pharma to Accelerate AI‑Driven Endocrine Drug Discovery

Fineline Cube Feb 6, 2026
Company Deals

Shanghai Pharma to Divest 30% Stake in Sino-American Squibb for $147M

Fineline Cube Feb 6, 2026
Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Policy / Regulatory

China’s NHSA Opens NRDL to AI and Digital Health Innovation, Unveils Scenario‑Driven Reimbursement Reform

Fineline Cube Feb 6, 2026
Company Drug

Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China

Fineline Cube Feb 6, 2026
Company Drug

Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial

Fineline Cube Feb 6, 2026
Company Deals

Mustang Bio, Inc. Enters Strategic Partnership with uBriGene for Cell and Gene Therapy

Fineline Cube May 19, 2023

US-based Mustang Bio, Inc. has announced a strategic partnership with uBriGene (Boston) Biosciences Inc., the...

Company Deals

Beijing Sun-Novo Secures Exclusive Rights to Kaneka’s Skin Patch Drugs in Licensing Deal

Fineline Cube May 19, 2023

China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced a licensing agreement with...

Company Deals

International Vaccine Institute and Nankai University Establish Joint Research Center for Vaccine Advancements

Fineline Cube May 19, 2023

The International Vaccine Institute (IVI), a non-profit international organization initiated by the United Nations Development...

Company Medical Device

MicroPort MedBot Receives NMPA Approval for Mona Lisa Prostate Puncture Robot System

Fineline Cube May 19, 2023

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that it has received marketing...

Policy / Regulatory

Liaoning-Led Alliance Launches Volume-Based Procurement Tender for Hernia and Dural Patches

Fineline Cube May 19, 2023

A 12-strong provincial procurement alliance, spearheaded by Liaoning province, has announced the initiation of a...

Company Deals

Asieris Pharmaceuticals Secures Exclusive Global Rights to UroViu’s Fluorescent Imaging Cystoscope

Fineline Cube May 19, 2023

China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has announced a strategic collaboration with US...

Company Drug

Abbisko Therapeutics and X4 Pharmaceuticals Announce Positive Phase III Results for Mavorixafor in WHIM Syndrome

Fineline Cube May 19, 2023

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) and its US partner X4 Pharmaceuticals Inc....

Company Deals

Shenzhen Kangtai Biological Partners with Saudi Importer for Pneumonia Vaccine Distribution

Fineline Cube May 19, 2023

China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced a strategic partnership with...

Company Drug

FibroGen’s Roxadustat Shows Positive Results in Phase III Chemotherapy-Induced Anemia Trial

Fineline Cube May 19, 2023

US-based FibroGen Inc. (NASDAQ: FGEN) has announced positive topline data from a Phase III trial...

Company

GenScipt Biotech Corp. Expands Oligonucleotide and Peptide Manufacturing in Zhenjiang

Fineline Cube May 19, 2023

China-based Contract Development and Manufacturing Organization (CDMO) GenScipt Biotech Corp. (HKG: 1548) has revealed the...

Company Drug

NMPA Approves Nanjing Sanhome’s Alfosbuvir for Chronic Hepatitis C Treatment

Fineline Cube May 18, 2023

Nanjing Sanhome Pharmaceutical Co., Ltd has announced that its Category 1 drug alfosbuvir has been...

Company Drug

Betta Pharmaceuticals Initiates Phase I/II Study for First-In-Class BsAb BPB-101

Fineline Cube May 18, 2023

China’s Betta Pharmaceuticals (SHE: 300558) has announced the enrollment of the first patient in a...

Company Drug

Antengene’s First-in-Class CD24 mAb ATG-031 Gets US FDA Approval for Phase I Study

Fineline Cube May 18, 2023

Antengene Corp., Ltd (HKG: 6996) has announced that it has received approval from the US...

Company Drug

BioRay Pharmaceutical’s Zuberitamab Approved by NMPA for CD20 Positive DLBCL Treatment

Fineline Cube May 18, 2023

BioRay Pharmaceutical Co., Ltd has announced that its drug zuberitamab has been approved by the...

Company Drug

WestVac Biopharma Receives FDA Approval for COVID-19 Protein Vaccines Targeting XBB Variants

Fineline Cube May 18, 2023

Chengdu-based WestVac Biopharma Co., Ltd has announced receiving clinical trial approval from the National Medical...

Company Drug

CARSgen Therapeutics Initiates Phase II Study for CT041 in Advanced Gastric Cancer

Fineline Cube May 18, 2023

China-based chimeric antigen receptor (CAR)-T cell specialist CARSgen Therapeutics Holdings Ltd (HKG: 2171) has announced...

Company Deals

National Vaccine & Serum Institute Partners with Corning Life Sciences to Foster Innovation

Fineline Cube May 18, 2023

The National Vaccine & Serum Institute has announced a partnership with Corning Life Sciences, aiming...

Company Drug

CDE Lists Three Home-Grown Drugs for Priority Review, Including Myopia Treatment

Fineline Cube May 18, 2023

The Center for Drug Evaluation (CDE) website has indicated that three home-grown drugs are on...

Company Medical Device

Grand Pharmaceutical’s Novasight Hybrid System Receives Marketing Approval in China

Fineline Cube May 18, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that its Novasight Hybrid System, a...

Company Deals

HitGen Inc. Enters Research Agreement with ARase Therapeutics to Discover Oncology Inhibitors

Fineline Cube May 18, 2023

China-based HitGen Inc. (SHA: 688222) has announced a research agreement with ARase Therapeutics, Inc. Under...

Posts pagination

1 … 479 480 481 … 621

Recent updates

  • Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging
  • Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China
  • Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial
  • Akeso’s Ivonescimab Secures Fifth Breakthrough Therapy Designation for Biliary Tract Cancer in China
  • Ascentage Pharma Secures NMPA Approval for APG‑3288 BTK Degrader Trial in Hematologic Malignancies
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Company Drug

Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China

Company Drug

Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial

Company Drug

Akeso’s Ivonescimab Secures Fifth Breakthrough Therapy Designation for Biliary Tract Cancer in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.